New Corporate Presentation
No summary for this filing – the full text is below.
Select text to share a quote on X · sign in to keep highlights & notes in your THAT notes
N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, is pleased to announce the publication of a new corporate presentation accompanied by a video update from CEO, Nigel Theobald.
Key points covered in the presentation include N4 Pharma's strategic focus on two key lead programs: N4 101 for Irritable Bowel Disease ("IBD") and ECP 105 for post-surgical scarring prevention, utilising the Company's proprietary delivery technologies, Nuvec® and LipTide™. The Company's aim is to advance preclinical studies and prepare for a Clinical Trial Authorisation ("CTA") / Investigational New Drug ("IND") filing in the coming years, while also pursuing licensing and platform collaboration opportunities.
Investors are invited to submit questions on the presentation via N4 Pharma's investor hub, and CEO Nigel Theobald will address these in a subsequent video. Register and submit questions at: https://investors.n4pharma.com/link/MP7A7e.
The full slide deck is available to view on N4 Pharma's investor hub here: https://investors.n4pharma.com/s/01e7a3
| N4 Pharma plc Nigel Theobald, CEO Luke Cairns, Executive Director | Via N4 Pharma Investor Hub https://investors.n4pharma.com/announcements |
| SP Angel Corporate Finance LLP Nominated Adviser and Joint Broker Matthew Johnson/Caroline Rowe (Corporate Finance) Vadim Alexandre/Abigail Wayne/Rob Rees (Corporate Broking) | Tel: +44(0)20 3470 0470 |
| Turner Pope Investments (TPI) Limited Joint Broker Andy Thacker James Pope | Tel: +44(0)20 3657 0050 |
| Investor hub Engage with us directly at N4 Pharma Investor Hub | Sign up at investors.n4pharma.com |
About N4 Pharma
N4 Pharma is a pre-clinical biotech company developing unique nucleic acid based products using its patented delivery systems Nuvec® and Liptide®. Its first two products are an oral anti-inflammatory product for IBD and an siRNA to knock down MRTF-B which reduces scarring post Glaucoma surgery. As well as these it is looking to develop further oncology and gene therapy products.
Its novel delivery systems are also available to third parties for licensing to develop their own products in oncology, gene therapy and vaccines for upfront payments, milestone payments and ultimately royalty payments once products reach the market.
It is also seeking partners or investors to take its initial products into phase 1 clinical trials.
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.